Limosilactobacillus reuteri RE225 alleviates gout by modulating the TLR4 / MyD88 / NF ‐ κ B inflammatory pathway and the Nrf2/ HO ‐1 oxidative stress pathway, and by regulating gut microbiota
Journal of the Science of Food and Agriculture · 2025
DOI: 10.1002/jsfa.13908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Science of Food and Agriculture, 2025. Verfasst von Yang Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-products, School of Marine Science, Ningbo University…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Limosilactobacillus reuteri, Toll-Like Receptor 4, NF-kappa B. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: General Project of Zhejiang Provincial Department of Education (Y202146257), Natural Science Foundation of Zhejiang Province (LTGC23C190001).
Abstract (Originalsprache)
BACKGROUND Gout poses a significant health threat. The use of Lactobacillus from the gut microbiota is one potential remedy. However, the intricate molecular mechanisms governing the impact of Lactobacillus on gout remain largely uncharted. In this study, a strain of Limosilactobacillus reuteri RE225 was separated from the gut of mice and colitis was treated with polypeptide intervention. RESULTS Limosilactobacillus reuteri RE225 reduced foot tumefaction markedly in mice with gout and extended the pain threshold time in their feet. It also improved the health of gut microbiota. Intervention with L. reuteri RE225 also suppressed the TLR4/MyD88/NF‐ κ B and nuclear factor erythroid 2‐related factor 2 (Nrf2)/heme oxygenase‐1 (HO‐1) pathways in the mice, reduced the levels of pro‐inflammatory cytokines – interleukin 1 β (IL‐1 β ), interleukin 6 (IL‐6), and tumor necrosis factor‐ α (TNF‐ α ) – and increased the level of the anti‐inflammatory cytokine interleukin 10 (IL‐10), thereby mitigating inflammation. CONCLUSION This study provides a theoretical basis for the comprehensive development of Limosilactobacillus reuteri and new ideas for the non‐pharmacological treatment of gout. © 2024 Society of Chemical Industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-products, School of Marine Science, Ningbo University, Ningbo, China.
- College of Biological and Environmental Science, Zhejiang Wanli University, Ningbo, China.
ORCID-Profile: Jiaojiao Han
Förderung
- General Project of Zhejiang Provincial Department of Education (Y202146257)
- Natural Science Foundation of Zhejiang Province (LTGC23C190001)
Zitieren
APA
Qin, Y., Zhou, Y., Xiong, J., Lu, C., Zhou, J., Su, X., & Han, J. (2025). Limosilactobacillus reuteri RE225 alleviates gout by modulating the TLR4 / MyD88 / NF ‐ κ B inflammatory pathway and the Nrf2/ HO ‐1 oxidative stress pathway, and by regulating gut microbiota. Journal of the Science of Food and Agriculture. https://doi.org/10.1002/jsfa.13908
Vancouver
Qin Y, Zhou Y, Xiong J, Lu C, Zhou J, Su X, et al. Limosilactobacillus reuteri RE225 alleviates gout by modulating the TLR4 / MyD88 / NF ‐ κ B inflammatory pathway and the Nrf2/ HO ‐1 oxidative stress pathway, and by regulating gut microbiota. Journal of the Science of Food and Agriculture. 2025. doi:10.1002/jsfa.13908
BibTeX
@article{Qin2025,
author = {Qin, Yang and Zhou, Yucong and Xiong, Jiayi and Lu, Chenyang and Zhou, Jun and Su, Xiurong and Han, Jiaojiao},
title = {Limosilactobacillus reuteri RE225 alleviates gout by modulating the TLR4 / MyD88 / NF ‐ κ B inflammatory pathway and the Nrf2/ HO ‐1 oxidative stress pathway, and by regulating gut microbiota},
journal = {Journal of the Science of Food and Agriculture},
year = {2025},
doi = {10.1002/jsfa.13908}
}
EUVIMED